Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 3/20 | 0.50 |
| ▸ | CA1 | P00915 | 3/20 | 0.44 |
| ▸ | CA2 | P00918 | 3/20 | 0.44 |
| ▸ | CA12 | O43570 | 2/20 | 0.44 |
| ▸ | CA9 | Q16790 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | NAAA | Q02083 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | STS | P08842 | 4/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.39 |
| ▸ | MMP1 | P03956 | 1/20 | 0.38 |
| ▸ | MMP9 | P14780 | 1/20 | 0.38 |
| ▸ | MMP12 | P39900 | 1/20 | 0.38 |
| ▸ | CES2 | O00748 | 1/20 | 0.38 |
| ▸ | CES1 | P23141 | 1/20 | 0.38 |
| ▸ | FABP7 | O15540 | 1/20 | 0.37 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL113152 | 1.00 | EPHX1 (0.50) | EPHX1CA1CA2CA12CA9 | |
| SCHEMBL1416449 | 1.00 | EPHX1 (0.50) | EPHX1CA1CA2CA12CA9 | |
| Ammonia Solution, Strong SCHEMBL3387866 | 0.97 | EPHX1 (0.48) | EPHX1CA1CA2CA12CA9 | |
| Hydrochloric Acid SCHEMBL28839888 | 0.97 | EPHX1 (0.48) | EPHX1CA1CA2CA12CA9 | |
| SCHEMBL112091 | 0.97 | — | — | |
| Oxalic Acid SCHEMBL31534669 | 0.93 | EPHX1 (0.45) | EPHX1CA1CA2CA12CA9 | |
| SCHEMBL10067466 | 0.92 | ATM (0.45) | EPHX1CA1CA2CA12CA9 | |
| SCHEMBL113287 | 0.92 | — | — | |
| Cyclohexylamine SCHEMBL11585176 | 0.91 | EPHX1 (0.44) | EPHX1CA1CA2CA12CA9 | |
| Methyl Carbamate SCHEMBL30201619 | 0.91 | EPHX1 (0.50) | EPHX1CA1CA2CA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1879856-B1 | ALKYL-, ALKENYL- AND ALKYNYL CARBAMATE DERIVATIVES, THE PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI AVENTIS (FR) | 2011-03-16 | — | — | EP | claimed |
| CN-101005857-A | Polypeptide protracting tags | NOVO NORDISK AS (DK) | 2007-07-25 | — | — | CN | claimed |
| WO-2024094637-A1 | PROCESS FOR THE PREPARATION OF CYCLIC KETONES | ARXADA AG (CH) | 2024-05-10 | — | — | WO | disclosed |
| US-20230233562-A1 | HETEROARYL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC USE | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2023-07-27 | — | — | US | disclosed |
| US-20230121556-A1 | COMPOUNDS FOR FAST AND EFFICIENT CLICK RELEASE | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2023-04-20 | — | — | US | disclosed |
| US-10927139-B2 | Chemically cleavable group | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2021-02-23 | — | — | US | disclosed |
| US-20210040062-A1 | AZOLE-SUBSTITUTED PYRIDINE COMPOUND | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2021-02-11 | — | — | US | disclosed |
| US-20200383984-A1 | HETEROARYL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC USE | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2020-12-10 | — | — | US | disclosed |
| EP-3418276-A1 | AZOLE-SUBSTITUTED PYRIDINE COMPOUND | Taisho Pharmaceutical Co., Ltd. (JP) | 2018-12-26 | — | — | EP | disclosed |
| CN-101878208-B | Substituted-quinoxaline-type-piperidine compounds and the uses thereof | PURDUE PHARMA L.P. (US) | 2014-10-15 | — | — | CN | disclosed |
| CN-102712676-A | Template-fixed peptidomimetics with CCR10 antagonistic activty | POLYPHOR AG | 2012-10-03 | — | — | CN | disclosed |
| EP-1879856-B1 | ALKYL-, ALKENYL- AND ALKYNYL CARBAMATE DERIVATIVES, THE PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI AVENTIS (FR) | 2011-03-16 | — | — | EP | disclosed |
| CN-101878208-A | Quinoxaline-type-piperidine compounds that replaces and uses thereof | PURDUE PHARMA LP | 2010-11-03 | — | — | CN | disclosed |
| CN-101595100-A | Piperidines as the heterocyclic substituted of ORL-1 part | PURDUE PHARMA LP (US) | 2009-12-02 | — | — | CN | disclosed |
| EP-1879856-A2 | ALKYL-, ALKENYL- AND ALKYNYL CARBAMATE DERIVATIVES, THE PREPARATION AND THERAPEUTIC USE THEREOF | Sanofi-Aventis (FR) | 2008-01-23 | — | — | EP | disclosed |
| CN-101005857-A | Polypeptide protracting tags | NOVO NORDISK AS (DK) | 2007-07-25 | — | — | CN | disclosed |
| WO-2006117461-A2 | ALKYL-, ALKENYL- ET ALKYNYL CARBAMATE DERIVATIVES, THE PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2006-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200383984-A1 | HETEROARYL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC USE | CDK9, IRAK1, CSNK1A1 | EPHX1 2321/4885CA1 3125/4885CA2 2457/4885 |
| US-10927139-B2 | Chemically cleavable group | SQLE, CTRL, ENO1 | EPHX1 88/4885CA1 211/4885CA2 3189/4885 |
| US-20230121556-A1 | COMPOUNDS FOR FAST AND EFFICIENT CLICK RELEASE | LTB4R, LTC4S, LTA4H | EPHX1 71/4885CA1 2384/4885CA2 2790/4885 |
| US-20230233562-A1 | HETEROARYL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC USE | CDK9, IRAK1, CSNK1A1 | EPHX1 2296/4885CA1 3217/4885CA2 2522/4885 |
| US-20210040062-A1 | AZOLE-SUBSTITUTED PYRIDINE COMPOUND | CYP2F1, CYP21A2, CYP11B1 | EPHX1 144/4885CA1 640/4885CA2 264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.